GRMLW
Greenland Mines LtdNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
—
Beta
2.43
52W High
$0.17
52W Low
$0.08
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Greenland Mines Ltd
Greenland Mines Ltd develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. The company is headquartered in Omaha, Nebraska.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -198.20% |
| Return on Assets | -74.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.14 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $104.55M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Data last updated: 4/8/2026